"Dr. Hana El Sahly, the FDA committee chair, said Guillain-Barre has an incidence of about 1 in 100,000 among people ages 60 and older. But in the vaccine trial, the rate was more like 1 in 9,000."
#GuillainBarre #RSVvaccine #Vaccines #Pfizer
https://www.cnbc.com/2023/04/06/rsv-adult-vaccine-pfizer-shot-monitored-for-guillain-barre.html
#GuillainBarre #RSVvaccine #Vaccines #Pfizer
https://www.cnbc.com/2023/04/06/rsv-adult-vaccine-pfizer-shot-monitored-for-guillain-barre.html
CNBC
Pfizer RSV vaccine for older adults should be monitored for nervous system condition Guillain-Barre, scientists say
Scientists said Pfizer's RSV vaccine for older adults should be monitored for Guillain-Barre, in an article published in the New England Journal of Medicine.
Twelve Infants Perish in Clinical Trial for #RSV Shot - #FDA Recommends Anyway
#Nuremberg2 #RSVvaccine
https://rumble.com/v2tsyfy-twelve-infants-perish-in-clinical-trial-for-rsv-shot-fda-recommends-anyway.html
#Nuremberg2 #RSVvaccine
https://rumble.com/v2tsyfy-twelve-infants-perish-in-clinical-trial-for-rsv-shot-fda-recommends-anyway.html
Rumble
Twelve Infants Perish in Clinical Trial for RSV Shot - FDA Recommends Anyway
Twelve Infants Perish in Clinical Trial for RSV Shot - FDA Recommends Anyway Four of the twelve infants’ deaths in the AstraZeneca trial were from cardiac arrest, and two died of SIDS (Sudden Infant D
The clinical trial showed a 17% increase in preterm labor and preterm birth in the women who took the #RSVvaccine during #Pregnancy.
#RightToKnow #InformedConsent
https://www.msn.com/en-us/health/medical/new-rsv-vaccine-is-better-protecting-babies-but-has-potential-link-to-preterm-birth/ar-AA1gXKRU
#RightToKnow #InformedConsent
https://www.msn.com/en-us/health/medical/new-rsv-vaccine-is-better-protecting-babies-but-has-potential-link-to-preterm-birth/ar-AA1gXKRU
#Moderna shares slide on concerns over drop in #RSVvaccine efficacy
https://www.yahoo.com/news/moderna-shares-slide-longer-term-152839352.html
https://www.yahoo.com/news/moderna-shares-slide-longer-term-152839352.html
Yahoo News
Moderna shares slide on concerns over drop in RSV vaccine efficacy
Data posted on Thursday ahead of an RSV conference next week showed an efficacy of about 63% after 8.6 months in preventing RSV-related respiratory disease, down from 84% at 3.3 months. Moderna's shares fell to $89 in morning trading, after closing down 5.7%…
#Moderna's #RSVvaccine is an #mRNA injection. The label claims the shot was 79% effective at preventing at least two symptoms of RSV, such as cough and fever. (It does not prevent the disease or transmission of the disease, it is '79% effective' at suppressing two symptoms).
#GeneTransferDrugs #InformedConsent
https://www.yahoo.com/news/us-fda-approves-modernas-rsv-150605330.html
#GeneTransferDrugs #InformedConsent
https://www.yahoo.com/news/us-fda-approves-modernas-rsv-150605330.html
Yahoo News
US FDA approves Moderna's RSV vaccine, its second marketed product
The U.S. Food and Drug Administration has approved Moderna's respiratory syncytial virus (RSV) vaccine, the company announced on Friday, giving it a shot at much-needed new revenue from a second product. Moderna's vaccine was approved by the FDA for the prevention…